Evidence map›Paper›PMID 37072923›Full record

ReviewIntestinal research2023

Does caffeine have a double-edged sword role in inflammation and carcinogenesis in the colon?

Emiko Mizoguchi, Takayuki Sadanaga, Toshiyuki Okada, Takanori Minagawa, Jun Akiba

Open access · diamondAbstract readReview
In one paragraph

Review in Intestinal research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 2 countries.

Emiko MizoguchiDepartment of Immunology, Kurume University School of Medicine, Kurume, Japan.
Takayuki SadanagaDepartment of Immunology, Kurume University School of Medicine, Kurume, Japan.
Toshiyuki OkadaDepartment of Immunology, Kurume University School of Medicine, Kurume, Japan.
Takanori MinagawaDepartment of Immunology, Kurume University School of Medicine, Kurume, Japan.
Jun AkibaDepartment of Diagnostic Pathology, Kurume University Hospital, Kurume, Japan.
Kurume University · JPKurume University Hospital · JP

Funding

Fukuoka Clinical Medical Research AwardIshibashi Foundation for the Promotion of ScienceJapanese Society for the Promotion of Science 18K07987Japanese Society for the Promotion of Science 21K07996Japan Society for the Women's Health Science
6 · The paper itself

Abstract

Caffeine (1,3,7-trimethylxanthine, also abbreviated to CAF) is a natural chemical with stimulant effects and is commonly included in many drinks and foods, including coffee, tea, cola, energy drinks, cocoa, chocolates, and so on. Our group previously reported that oral administration of CAF efficiently suppressed the development of intestinal inflammation in a dextran sulfate sodium (DSS)-induced murine acute colitis model by suppressing the expression of chitinase 3-like 1, one of the mammalian chitinases without enzymatic activity. Chitinases are hydrolytic enzymes that break down chitin, a polymer of N-acetylglucosamine, and chitinase-like proteins have no enzymatic activity with preserving chitin-binding ability. CAF binds a cleft of the chitinase active site and plays a role as a pan-chitinase inhibitor. Although CAF showed an anti-inflammatory effect in the above model, oral administration of low-dose CAF with 10% sucrose showed potentially neoplastic effects in colonic epithelial cells in a DSS-induced murine chronic colitis model. In this review, we would like to discuss the pros and cons of coffee/CAF in colonic inflammation and neoplasia with an example of pathological finding.

Indexed as

CaffeineChitinase 3-like 1Colitis-associated neoplasmsInflammatory bowel diseaseSucrose

Identifiers

PMID37072923
PMCPMC10397549
OpenAlexW4366352077

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.